Gelonghui, January 3 | Shu Taishen (300204.SZ) announced that recently, Shu Taishen (Beijing) Biopharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” (Notice No.: 2024LP00023) for STSA-1001 injection to treat cancer pain from the State Drug Administration, agreeing to carry out clinical trials on cancer pain with this product.

STSA-1001 injection is a recombinant anti-NGF wholly human IgG1 monoclonal antibody injection. The antibody can effectively block the binding of NGF to its receptors, thereby effectively inhibiting the NGF signaling pathway in pain diseases and reducing neurological pain caused by excessive innervation; at the same time, it can also effectively block NGF's regulatory effects on harmful ion channels/receptors and the expression level of harmful genes, reduce injurious pain, and thus play a role in treating pain.

The company submitted an STSA-1001 injection clinical trial application to the State Drug Administration in October 2023, and obtained clinical trial approval in January 2024.